Thursday, April 26, 2012

Transcept seeks $37M from stock offering

Transcept Pharmaceuticals Inc. would use some of the $37.6 million it hopes to net from a public stock offering to sell its FDA-approved middle-of-the-night sleep drug and to move forward with a drug for obsessive compulsive disorder. Transcept priced the offering of 4.5 million shares at $9 per share.

No comments:

Post a Comment